A New Model Improves Outcomes in Impairment Studies

Sponsored by: Covance

Focused on:

  • Renal
  • Hepatic
  • Clinical Trial

Date: 14 November


Time: 11AM EST

Industry standard timelines for end-to-end completion of a typical renal or hepatic impairment trial may be up to 18-22 months. Over the past 10 years, Covance has developed a built-for-purpose model for executing impairment studies resulting in a 36% reduction of time for end-to-end services. The success of these studies is built on three pillars that can positively influence your clinical trial outcome:

1. Medical and scientific oversight
2. Dedicated site network
3. Experienced project management team

Join us for an interactive webinar with Geoffrey Roske, who leads project management teams responsible for the oversight and execution of these critically important impairment studies. He will share his experience about when and how to put these pillars to work to improve the outcome of your label registration submission.

Presented by

Geoffrey Roske,

Director, Project Management, Covance Clinical Pharmacology Services

Geoff is a Director of Project Management within Covance clinical pharmacology services. He has over 20 years of experience in early clinical research across a variety of therapeutic areas. In his role today, Geoff leads a core project team and facilitates relationships with extended teams to deliver results on time and within budget for his clients. He holds a BS in Biological Sciences, an MBA and is a certified Six Sigma Black Belt.

Key Learning Objectives

  • Learn more about the three key pillars to successfully execute your renal studies
  • Determine how to use the pillars to improve outcomes
  • Understand when to execute to help reduce time for end-to-end services


  • Hepatologist
  • Nephrologist
  • Site Staff
  • Clinical Pharmacology Operations
  • Medical Director
  • Renal/Hepatic Impairment Specialists